• N4-Acetylcytidine: Enhancing RNA Epigenetics Research Workfl

  2026-05-26

  N4-Acetylcytidine unlocks precise, reproducible analysis of RNA acetylation and nucleotide processing enzyme specificity. This article details experimental workflows, troubleshooting strategies, and the latest structural insights to empower advanced RNA epigenetics research.

• LGK-974: PORCN Inhibitor Workflows for Wnt-Driven Cancer Mod

  2026-05-25

  LGK-974 empowers translational researchers to precisely block Wnt secretion and dissect pathway dependencies in pancreatic and other Wnt-driven cancers. This guide bridges mechanistic rationale with actionable workflows and troubleshooting, leveraging new evidence for optimized experimental design.

• Dlin-MC3-DMA: Ionizable Cationic Liposome for RNA Delivery

  2026-05-25

  Dlin-MC3-DMA stands at the forefront of ionizable cationic liposome technologies, enabling potent, targeted siRNA and mRNA delivery. This guide distills experimental best practices, ML-driven workflow refinements, and troubleshooting tips for maximizing success in hepatic gene silencing, immunomodulation, and beyond.

• Sodium Overload Disrupts Mitochondrial Energy in NECSO Execu

  2026-05-24

  Qiao et al. reveal that sodium influx via TRPM4 channels disrupts mitochondrial energy metabolism by suppressing oxidative phosphorylation and the TCA cycle, leading to necrosis through NECSO. This mechanistic insight connects ion dysregulation to mitochondrial dysfunction and has practical implications for metabolic adaptation and apoptosis pathway research.

• HOXC8 Suppresses Pyroptosis in NSCLC via Caspase-1 Regulatio

  2026-05-23

  This study reveals that HOXC8, a transcription factor overexpressed in non-small cell lung carcinoma (NSCLC), inhibits pyroptotic cell death by suppressing caspase-1 expression. The findings clarify a unique mechanism of tumor survival in NSCLC and highlight the importance of epigenetic regulation in caspase signaling, with potential implications for inflammation research and apoptosis assays.

• Capsaicin: Mechanistic Leverage for Translational Pain Resea

  2026-05-22

  Explore how (E)-Capsaicin’s dual action—TRPV1 ion channel activation and KDM1A inhibition—enables refined model design and clinical translation in pain and inflammation research. This article synthesizes mechanistic insights, recent competitive advances, and strategic guidance for next-generation assay development, positioning APExBIO’s Capsaicin (SKU C6366) as a cornerstone for innovative translational workflows.

• Zolmitriptan (SKU B2261): Reliable 5-HT1B Agonist for Migrai

  2026-05-22

  This article addresses common challenges in serotonin receptor pharmacology and migraine research, focusing on the reproducibility, solubility, and workflow integration of Zolmitriptan (SKU B2261). Through scenario-driven Q&A and data-backed protocol guidance, biomedical scientists gain actionable strategies for enhancing cell-based assays and model reliability. APExBIO’s Zolmitriptan stands out for its purity and validated use in high-sensitivity experimental workflows.

• Dual Fluorescent Immunoassay for Simultaneous Detection of M

  2026-05-21

  This study introduces a computationally guided strategy to develop monoclonal antibodies enabling highly sensitive, simultaneous detection of amatoxins and phallotoxins in mushrooms. The dual-target fluorescent immunochromatographic assay (DTFICA) offers significant advances for rapid on-site toxin screening, addressing key public health and food safety needs.

• CX-4945 (Silmitasertib): Precision CK2 Inhibition Beyond Onc

  2026-05-21

  Explore how CX-4945 (Silmitasertib) uniquely advances CK2 inhibition in cancer biology and emerging antiviral research. This in-depth review demystifies its mechanism, practical applications, and strategic value for translational scientists.

• Sodium Picosulfate: Mechanistic Insights and Gut–Liver–Brain

  2026-05-20

  Explore the mechanistic depth of Sodium Picosulfate in gut–liver–brain axis research, including its unique impact on electrolyte modulation and relevance for neuroinflammation studies—a perspective not found in standard stimulant laxative guides.

• Hyaluronated Lipid Nanoparticles for Transdermal PTEN mRNA T

  2026-05-20

  This study introduces a hyaluronate-conjugated lipid nanoparticle system for the transdermal delivery of PTEN mRNA, targeting melanoma through improved skin penetration and tumor selectivity. The HA-LNP formulation offers a promising, minimally invasive approach for localized mRNA-based cancer immunotherapy, addressing both delivery efficiency and immune evasion.

• HR Repair Gene Profiling Predicts PARP Inhibitor Response in

  2026-05-19

  Borchert et al. provide critical insight into how homologous recombination repair (HRR) gene expression patterns, particularly the BRCAness phenotype, stratify malignant pleural mesothelioma (MPM) subtypes with differential susceptibility to PARP inhibition. Their findings support gene-guided combination therapies for improving outcomes in hard-to-treat MPM.

• Pexmetinib (ARRY-614): Applied Protocols for Cytokine Inhibi

  2026-05-19

  Pexmetinib (ARRY-614) stands out as a robust dual inhibitor for dissecting p38 MAPK and Tie2-driven cytokine pathways in inflammation and myelodysplastic syndromes research. This guide translates recent conformational insights and validated workflows into actionable protocols, troubleshooting, and optimization strategies, empowering researchers to achieve reproducible, interpretable results.

• Fucoidan Mitigates Irinotecan-Induced Steatohepatitis via Gu

  2026-05-18

  This study elucidates the mechanistic basis of chemotherapy-induced steatohepatitis using Irinotecan (CPT-11) as a clinically relevant model. The paper demonstrates that fucoidan restores gut barrier integrity, reduces harmful neutrophil extracellular trap formation, and alleviates liver injury—offering a targeted strategy for managing hepatotoxicity in chemotherapeutic regimens.

• RITA (NSC 652287): Enabling Precision in Renal Carcinoma Res

  2026-05-18

  RITA (NSC 652287) stands out as a benchmark MDM2-p53 interaction inhibitor, offering unmatched selectivity and efficacy in both in vitro and in vivo renal carcinoma models. This article delivers actionable protocols, troubleshooting strategies, and critical insights for maximizing data quality in apoptosis and viability assays.

16138 records 1/1076 page Next 12345 下5页 Last page